Investor Presentaiton

With the acquisition of Nine Continents, we are executing on the option to enter the attractive OAB market with Intibia Overactive bladder (OAB) market +80m people globally suffer from OAB symptoms ~40% of the OAB patient population seek treatment -3m are candidates for 3rd line therapies¹) 1bn USD 3rd line therapies market, growing high-single digits Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive procedure than SNS Less time-intensive Established data on tibial nerve stimulation efficacy ITNS complete in single procedure Procedure under local anesthesia No need for patients to make regular visits Providers can treat patients in one session PTNS established clinical efficacy Urologist familiar with PTNS story Nine Continents Medical Inc NINE CONTINENTS MEDICAL Nine Continents Medical Inc is an early-stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder The device is an implantable tibial nerve stimulator (ITNS), a miniaturized, self-powered unit placed in the lower leg under local anesthesia during a short, minimally invasive procedure Coloplast began pivotal studies in early 2022, with the ambition to obtain pre-market approval for a Class III device in the US and EU market. Launch expected in 2025/2026 Transaction The acquisition price consists of a USD 145 million upfront cash payment and an additional contingent future milestone payment The acquisition is debt financed using existing credit facilities and has no impact on Coloplast's dividend policy or long-term financial guidance Why Coloplast's ITNS solution? ✓ No need for patient compliance in therapy Long battery life ✓ Focused stimulation field near target nerve 73 1) Existing 3rd line therapies for OAB includes sacral neuromodulation, botox and percutaneous tibial nerve stimulation (PTNS) Coloplast

View entire presentation